News Neurotech International Limited

Equities

NTI

AU000000NTI9

Market Closed - Australian S.E. Other stock markets 07:10:05 29/04/2024 BST			5-day change	1st Jan Change
0.09 ^AUD	0.00%		-2.17%	+30.43%

04-17	Neurotech's Phase II/III NTIASD2 Clinical Trial for Children with Autism Meets Primary Endpoint	MT
04-17	Neurotech International Completes AU$10 Million Capital Raise	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Neurotech's Phase II/III NTIASD2 Clinical Trial for Children with Autism Meets Primary Endpoint	04-17	MT
Neurotech International Completes AU$10 Million Capital Raise	04-17	MT
Rice Biotech Launch Pad startup Motif Neurotech announces peer-reviewed publication on wireless cortical stimulator for precise neuromodulation	04-15	AQ
Neurotech International Concludes Phase II/III NTIASD2 Trial for Children with Autism	04-10	MT
Neurotech International Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-26	CI
Neurotech Receives Human Research Ethics Committee Approval to Extend Autism Trial	02-12	MT
Neurotech's ASD Drug Trials Exceed 90 Weeks	02-07	MT
Neurotech International Secures Approval to Advance Cerebral Palsy Trial; Shares Rise 6%	01-29	MT
Neurotech International Completes Enrolment for Phase 2/3 Autism Spectrum Trial	12-19	MT
Neurotech International Secures Ethics Approval for Use of Autism Spectrum Medication in Adults	12-04	MT
Neurotech International Secures AU$3 Million R&D Tax Rebate for Fiscal Year 2023	11-14	MT
Retinitis Pigmentosa Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	11-13	AQ
Butterfly Network Announces 5-Year Co-Development Agreement with Forest Neurotech for Next-generation Brain Computer Interfaces Using Ultrasound-on-Chip Technology	25/10/23	AQ
Neurotech International Completes Enrollment for Rett Syndrome Trial	26/09/23	MT
Alex Gorsky Joins Neurotech's Board as Lead Director	14/09/23	AQ
Neurotech International Completes Treatment for Last Patient in Phase I/II PANDAS/PANS Clinical Trial	31/08/23	MT
Neurotech International Limited Reports Earnings Results for the Full Year Ended June 30, 2023	30/08/23	CI
Neurotech International Secures Ethics Approval for Clinical Trial of Neurological Medication	10/07/23	MT
Neurotech International Secures Ethics Approval to Extend Use of Medication in Pediatric Trial	30/05/23	MT
Neurotech International Completes Patient Recruitment for Neuropsychiatric Disorder Treatment Trial	03/05/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Neurotech International Limited

Equities

NTI

AU000000NTI9

Summary

Filters